Improved overall survival in patients with advanced systemic mastocytosis treated with avapritinib versus real-world therapy based on mutation-adjusted risk score (MARS) stratification
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Andreas Reiter, Johannes Luebke, Jason Gotlib, Ivan Alvarez-Twose, Deepti Radia, Priyanka Bobbili, Aolin Wang, Saša Dimitrijević, Olivier Ponet, Erin Sullivan, Juliana Schwaab, Ilene Galinsky, Cecelia Perkins, Wolfgang Sperr, Priya Sriskandarajah, Manasi Mohan, Anyu Zhu, Mei Sheng Duh, Peter Valent, Daniel Deangelo, Julien Rossignol, Olivier Hermine
Institutions: Heidelberg University, University Medical Centre Mannheim, Stanford Medicine, Stanford Cancer Institute, Stanford University, Hospital Virgen del Valle, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, Analysis Group (United States), Blueprint Medicines (United States), Dana-Farber Cancer Institute, Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Hôpital Necker-Enfants Malades, Institut Necker Enfants Malades, Institut des Maladies Génétiques Imagine
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4417014959
Cites:
Cited by:
Related to: